HC Wainwright set a $20.00 price objective on Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) in a research report sent to investors on Monday, March 12th. The brokerage currently has a buy rating on the stock.
Separately, Zacks Investment Research downgraded shares of Rexahn Pharmaceuticals from a buy rating to a hold rating in a research report on Thursday, January 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $13.75.
Shares of RNN stock opened at $1.67 on Monday. Rexahn Pharmaceuticals has a fifty-two week low of $1.51 and a fifty-two week high of $7.10. The company has a market cap of $52.33, a PE ratio of -1.64 and a beta of -0.35.
An institutional investor recently bought a new position in Rexahn Pharmaceuticals stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 49,167 shares of the company’s stock, valued at approximately $119,000. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 0.16% of Rexahn Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.
TRADEMARK VIOLATION WARNING: “Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) PT Set at $20.00 by HC Wainwright” was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.thelincolnianonline.com/2018/03/21/rexahn-pharmaceuticals-rnn-pt-set-at-20-00-by-hc-wainwright.html.
Rexahn Pharmaceuticals Company Profile
Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.
Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.